Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Jaejun, Yang Keungmo, Han Ji Won, Sung Pil Soo, Jang Jeong Won, Yoon Seung Kew, Cho Hee Sun, Yang Hyun, Bae Si Hyun, Kim Ji Hoon, Nam Heechul, Kim Chang Wook, Lee Hae Lim, Kim Hee Yeon, Lee Sung Won, Lee Ahlim, Song Do Seon, Song Myeong Jun, Nam Soon Woo, Kwon Jung Hyun, Lee Soon Kyu
Аннотация
PURPOSE: Given the limited data on the effectiveness of atezolizumab plus bevacizumab (Ate/Bev) in patients with hepatocellular carcinoma with a Child-Pugh score (CPS) of 7, this study aims to evaluate the treatment's efficacy in this population and identify specific CPS 7 subgroups that may benefit from it.
EXPERIMENTAL DESIGN: This study included patients with advanced hepatocellular carcinoma who received Ate/Bev as first-line therapy between September 2020 and December 2023 at seven university hospitals. The primary outcome was overall survival (OS), whereas secondary outcomes included progression-free survival (PFS) and treatment response.
RESULTS: Among the 374 included patients, those with CPS 5 (n = 169) demonstrated the highest OS and PFS, followed by patients with CPS 6 (n = 105) and CPS 7 (n = 100; P < 0.05). For the variables comprising CPS, the HR for OS increased with elevated total bilirubin levels and was lower in patients with mild ascites (P < 0.05). The HR for OS tended to increase as albumin levels dropped to 2.8 g/dL. Based on these findings, patients with CPS 7 were further classified into two subgroups: favorable (total bilirubin <2 mg/dL, 3.5 ≥ albumin ≥ 2.8 g/dL, mild ascites, and absence of hepatic encephalopathy) and unfavorable (other CPS 7). Compared with patients with CPS 6, those in the favorable CPS 7 group exhibited comparable OS and PFS, whereas patients with unfavorable CPS 7 had significantly lower OS and PFS (P < 0.05). These findings were consistently observed in the multivariate analysis.
CONCLUSIONS: This study suggests that Ate/Bev treatment can be effective in a subset of patients with CPS 7, highlighting the potential to broaden treatment eligibility for this population. See related commentary by Li and Kelley, p. 4220.
EXPERIMENTAL DESIGN: This study included patients with advanced hepatocellular carcinoma who received Ate/Bev as first-line therapy between September 2020 and December 2023 at seven university hospitals. The primary outcome was overall survival (OS), whereas secondary outcomes included progression-free survival (PFS) and treatment response.
RESULTS: Among the 374 included patients, those with CPS 5 (n = 169) demonstrated the highest OS and PFS, followed by patients with CPS 6 (n = 105) and CPS 7 (n = 100; P < 0.05). For the variables comprising CPS, the HR for OS increased with elevated total bilirubin levels and was lower in patients with mild ascites (P < 0.05). The HR for OS tended to increase as albumin levels dropped to 2.8 g/dL. Based on these findings, patients with CPS 7 were further classified into two subgroups: favorable (total bilirubin <2 mg/dL, 3.5 ≥ albumin ≥ 2.8 g/dL, mild ascites, and absence of hepatic encephalopathy) and unfavorable (other CPS 7). Compared with patients with CPS 6, those in the favorable CPS 7 group exhibited comparable OS and PFS, whereas patients with unfavorable CPS 7 had significantly lower OS and PFS (P < 0.05). These findings were consistently observed in the multivariate analysis.
CONCLUSIONS: This study suggests that Ate/Bev treatment can be effective in a subset of patients with CPS 7, highlighting the potential to broaden treatment eligibility for this population. See related commentary by Li and Kelley, p. 4220.